Prot#CINC424B2301: Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care (The RESPONSE Trial)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/23/11 → 9/23/17

Funding

  • Parexel (CINC424B2301 // CINC424B2301)
  • Incyte Corporation (CINC424B2301 // CINC424B2301)